Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study
Research output: Contribution to journal › Journal article › Research › peer-review
Jørgen Matz, Claus Graff, Petri J. Vainio, Antero Kallio, Astrid Maria Højer, Johannes J. Struijk, Jørgen K. Kanters, Mads Peter Andersen, Egon Toft
Nalmefene is an orally administered competitive opioid receptor antagonist targeted at reducing alcohol consumption in alcohol-dependent patients. As part of the regulatory requirements for drug approval, the potential of novel compounds for causing unwanted proarrhythmia should be studied in a thoroughly designed clinical QT/corrected QT (QTc) study (International Conference on Harmonisation [ICH] E14 guideline).
|Journal||Clinical Drug Investigation|
|Number of pages||13|
|Publication status||Published - 2011|
- Adult, Anti-Infective Agents, Arrhythmias, Cardiac, Aza Compounds, Biomarkers, Pharmacological, Dose-Response Relationship, Drug, Double-Blind Method, Electrocardiography, Female, Guidelines as Topic, Heart Rate, Humans, Long QT Syndrome, Male, Naltrexone, Narcotic Antagonists, Placebos, Prospective Studies, Quinolines, Treatment Outcome, Young Adult